| Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study M Crump, SS Neelapu, U Farooq, E Van Den Neste, J Kuruvilla, J Westin, ... Blood 130 (16), 1800-1808, 2017 | 1539 | 2017 |
| Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study E Galanis, JC Buckner, MJ Maurer, JI Kreisberg, K Ballman, J Boni, ... Journal of Clinical Oncology 23 (23), 5294-5304, 2005 | 855 | 2005 |
| Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from … C Casulo, M Byrtek, KL Dawson, X Zhou, CM Farber, CR Flowers, ... Journal of Clinical Oncology 33 (23), 2516-2522, 2015 | 820 | 2015 |
| ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes ER Parrilla Castellar, ES Jaffe, JW Said, SH Swerdlow, RP Ketterling, ... Blood, The Journal of the American Society of Hematology 124 (9), 1473-1480, 2014 | 513 | 2014 |
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study E Galanis, KA Jaeckle, MJ Maurer, JM Reid, MM Ames, JS Hardwick, ... Journal of clinical oncology 27 (12), 2052-2058, 2009 | 429 | 2009 |
| Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy MJ Maurer, H Ghesquières, JP Jais, TE Witzig, C Haioun, CA Thompson, ... Journal of Clinical Oncology 32 (10), 1066-1073, 2014 | 415 | 2014 |
| Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303 NL Bartlett, WH Wilson, SH Jung, ED Hsi, MJ Maurer, LD Pederson, ... Journal of clinical oncology 37 (21), 1790-1799, 2019 | 381 | 2019 |
| Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Specialized Program of Research … BK Link, MJ Maurer, GS Nowakowski, SM Ansell, WR Macon, SI Syrbu, ... Journal of Clinical Oncology 31 (26), 3272-3278, 2013 | 344 | 2013 |
| Non‐H odgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the N ational C ancer D ata B ase from 1998 to 2011 M Al‐Hamadani, TM Habermann, JR Cerhan, WR Macon, MJ Maurer, ... American journal of hematology 90 (9), 790-795, 2015 | 310 | 2015 |
| Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma MT Drake, MJ Maurer, BK Link, TM Habermann, SM Ansell, IN Micallef, ... Journal of clinical oncology 28 (27), 4191-4198, 2010 | 279 | 2010 |
| The ratios of CD8+ T cells to CD4+ CD25+ FOXP3+ and FOXP3-T cells correlate with poor clinical outcome in human serous ovarian cancer CC Preston, MJ Maurer, AL Oberg, DW Visscher, KR Kalli, LC Hartmann, ... PloS one 8 (11), e80063, 2013 | 275 | 2013 |
| A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival PD Brown, MJ Maurer, TA Rummans, BE Pollock, KV Ballman, JA Sloan, ... Neurosurgery 57 (3), 495-504, 2005 | 245 | 2005 |
| Low‐dose, single‐agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group SM Ansell, DJ Inwards, KM Rowland Jr, PJ Flynn, RF Morton, DF Moore Jr, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2008 | 242 | 2008 |
| Early event status informs subsequent outcome in newly diagnosed follicular lymphoma MJ Maurer, E Bachy, H Ghesquières, SM Ansell, GS Nowakowski, ... American journal of hematology 91 (11), 1096-1101, 2016 | 235 | 2016 |
| Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders IM Ghobrial, TM Habermann, MJ Maurer, SM Geyer, KM Ristow, ... Journal of clinical oncology 23 (30), 7574-7582, 2005 | 226 | 2005 |
| Prospective study of quality of life in adults with newly diagnosed high-grade gliomas PD Brown, KV Ballman, TA Rummans, MJ Maurer, JA Sloan, BF Boeve, ... Journal of neuro-oncology 76, 283-291, 2006 | 223 | 2006 |
| Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer SJ Weroha, MA Becker, S Enderica-Gonzalez, SC Harrington, AL Oberg, ... Clinical Cancer Research 20 (5), 1288-1297, 2014 | 218 | 2014 |
| Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts C Sarkozy, MJ Maurer, BK Link, H Ghesquieres, E Nicolas, CA Thompson, ... Journal of Clinical Oncology 37 (2), 144-152, 2019 | 215 | 2019 |
| Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation M Gupta, JJ Han, M Stenson, M Maurer, L Wellik, G Hu, S Ziesmer, ... Blood, The Journal of the American Society of Hematology 119 (12), 2844-2853, 2012 | 204 | 2012 |
| Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma INM Micallef, MJ Maurer, GA Wiseman, DA Nikcevich, PJ Kurtin, ... Blood, The Journal of the American Society of Hematology 118 (15), 4053-4061, 2011 | 202* | 2011 |
James CerhanMayo Clinic在 mayo.edu 的电子邮件经过验证
